Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Clinton Yam

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

C. Yam1, S. Seth2, K.R. Hess3, E.A. Mittendorf4, R.K. Murthy1, S. Damodaran1, T. Helgason1, L. Huo5, A.M. Thompson6, M. Barton7, M.L. Huang8, E.M. Arribas8, D.L. Lane8, G.M. Rauch8, B.E. Adrada8, M.Z. Gilcrease5, J.T. Chang9, S.L. Moulder1

Author affiliations

  • 1 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston/US
  • 3 Biostatistics, The University of Texas MD Anderson Cancer Center, Houston/US
  • 4 Surgical oncology, Dana-Farber Cancer Insitute, Boston/US
  • 5 Pathology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 6 Breast Surgical oncology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 7 Epigenetics And Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston/US
  • 8 Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 9 Bioinformatics And Computational Biology, The University of Texas MD Anderson Cancer Center, Houston/US
More

Resources

Abstract 2260

Background

MpBCs are morphologically heterogeneous, frequently triple-negative and resistant to chemotherapy. To better understand why MpBCs are resistant to chemotherapy, we investigated associations between response to NAST and clinical, morphologic, as well as molecular characteristics in a cohort of MpBC patients (pts).

Methods

19 MpBC pts were identified from a prospective cohort of 242 triple-negative breast cancer (TNBC) pts treated with anthracycline-based NAST. Histologic subtype of MpBC was determined by light microscopy. TNBC subtypes were determined using the Vanderbilt gene expression signatures (GES). Residual cancer burden (RCB) was assessed after surgery.

Results

Of the 19 MpBCs, 37% (7/19) were matrix producing and 63% (12/19) were not. Analysis of GES revealed the following subtype distributions: mesenchymal (M)=32% (6/19), mesenchymal stem-like (MSL)=11% (2/19), basal-like 2 (BL2)=32% (6/19), immunomodulatory (IM)=11% (2/19), unstable (UNS)=11% (2/19), basal-like 1 (BL1)=5% (1/19). Fifty-seven percent (4/7) and 33% (4/12) of the matrix producing and non-matrix producing MpBCs were of the M/MSL subtype, respectively. Twenty-one percent (4/19) of pts had a pathologic complete response (pCR)/minimal residual disease (RCB-I) following NAST. MpBCs that were matrix producing or of the M/MSL subtype were associated with worse response to NAST as none (0/11) of the pts with MpBC that was matrix producing and/or of the M/MSL subtype had a pCR/RCB-I, compared with 50% (4/8) of the remaining pts (p = 0.018).Table: 228P

Associations between response to NAST and clinical, morphological as well as molecular characteristics

pCR/RCB-I (n = 4)RCB-II/III (n = 15)
Median age (range)57.3 (42.4-67.2)57.8 (34.2-74.0)
Mean tumor size - cm (SD)2.4 (1.2)4.7 (3.8)
Clinical nodal status
Negative - n (%)4 (25)12 (75)
Positive - n (%)03 (100)
Stage
I - n (%)2 (40)3 (60)
II - n (%)2 (20)8 (80)
III - n (%)04 (100)
Histologic grade
1 - n (%)01 (100)
2 - n (%)1 (25)3 (75)
3 - n (%)3 (21)11 (79)
Metaplastic subtype
Matrix producing - n (%)07 (100)
Non-matrix producing - n (%)4 (33)8 (67)
TNBC subtype
M/MSL - n (%)08 (100)
BL1/2 - n (%)3 (43)4 (57)
Other - n (%)1 (25)3 (75)

Conclusions

Analysis of GES suggest that MpBC is enriched for subtypes less likely to achieve pCR/RCB-I with NAST (BL2, M, MSL). Matrix-producing (light microscopy) and the M/MSL subtypes (GES) appear to be associated with resistance to anthracycline-based NAST in MpBC.

Clinical trial identification

Legal entity responsible for the study

The University of Texas MD Anderson Cancer Center.

Funding

National Comprehensive Cancer Network (NCCN) Oncology Research Program, The MD Anderson Cancer Center Moonshots Program, CPRIT Multi-Investigator Research Award (MIRA).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings